ArticleNeuro-oncology practice2024

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.

Katherine B Peters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.